<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="rcdp" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">rcdp</book-part-id>
      <title-group>
        <title>Rhizomelic Chondrodysplasia Punctata Type 1</title>
        <alt-title alt-title-type="alt-title">Synonym: RCDP1</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Braverman</surname>
            <given-names>Nancy E</given-names>
          </name>
          <degrees>MS, MD</degrees>
          <email>nancy.braverman@mcgill.ca</email>
          <aff>Departments of Human Genetics and Pediatrics<break/>McGill University - Montreal Children's Hospital Research Institute<break/>Montreal, Quebec, Canada</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moser</surname>
            <given-names>Ann B</given-names>
          </name>
          <degrees>BA</degrees>
          <email>mosera@kennedykrieger.org</email>
          <aff>Department of Neurogenetics <break/>Kennedy Krieger Institute <break/>Baltimore, Maryland</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Steinberg</surname>
            <given-names>Steven J</given-names>
          </name>
          <degrees>PhD</degrees>
          <email>steinbergs@kennedykrieger.org</email>
          <aff>Department of Neurogenetics <break/>Kennedy Krieger Institute <break/>Baltimore, Maryland</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2001-11-16" date-type="created">
          <day>16</day>
          <month>11</month>
          <year>2001</year>
        </date>
        <date iso-8601-date="2012-09-13" date-type="updated">
          <day>13</day>
          <month>9</month>
          <year>2012</year>
        </date>
        <date iso-8601-date="2005-02-07" date-type="revised">
          <day>7</day>
          <month>2</month>
          <year>2005</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="retinoblastoma" document-type="chapter">Retinoblastoma</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="riboflavin-tn" document-type="chapter">Riboflavin Transporter Deficiency Neuronopathy</related-object>
      <abstract id="rcdp.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Rhizomelic chondrodysplasia punctata type 1 (RCDP1) classic type, a peroxisome biogenesis disorder (PBD), is characterized by proximal shortening of the humerus and to a lesser degree the femur (rhizomelia), punctate calcifications in cartilage with epiphyseal and metaphyseal abnormalities (chondrodysplasia punctata, or CDP), coronal clefts of the vertebral bodies, and cataracts that are usually present at birth or appear in the first few months of life. Birth weight, length, and head circumference are often at the lower range of normal; postnatal growth deficiency is profound. Intellectual disability is severe, and the majority of children develop seizures. Most affected children do not survive the first decade of life; a proportion die in the neonatal period. A milder phenotype in which all affected individuals have congenital cataracts and chondrodysplasia is now recognized; some do not have rhizomelia, and some have less severe intellectual disability and growth deficiency.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of RCDP1 is based on clinical findings and confirmed by biochemical or molecular genetic testing. Biochemical tests of peroxisome function include: red blood cell concentration of plasmalogens (deficient), plasma concentration of phytanic acid (elevated), and plasma concentration of very long chain fatty acids (VLCFA) (normal), which has consistently predicted the PEX7 receptor defect in RCDP1. <italic toggle="yes">PEX7</italic>, which encodes the receptor for a subset of peroxisomal matrix enzymes, is the only gene in which pathogenic variants are known to cause RCDP1.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Management is supportive and limited by the multiple handicaps present at birth and poor outcome. Cataract extraction may restore some vision. Physical therapy is recommended to improve contractures; orthopedic procedures may improve function in some individuals.</p>
          <p><italic toggle="yes">Prevention of primary manifestations</italic>: Dietary restriction of phytanic acid to avoid the consequences of phytanic acid accumulation over time may benefit individuals with milder forms of RCDP.</p>
          <p><italic toggle="yes">Prevention of secondary manifestations</italic>: Poor feeding and recurrent aspiration may necessitate placement of a gastrostomy tube; attention to respiratory function with administration of influenza vaccine and RSV monoclonal antibody; docosohexanoic acid (DHA) supplementation in those who are deficient.</p>
          <p><italic toggle="yes">Surveillance</italic>: Monitoring of growth and development and regular assessments for seizure control, vision, hearing, contractures, and orthopedic complications.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>RCDP1 is inherited in an autosomal recessive manner. At conception, each sib of a proband has a 25% chance of inheriting both pathogenic alleles and being affected, a 50% chance of inheriting one pathogenic allele and being an unaffected carrier, and a 25% chance of inheriting both normal alleles. Once the pathogenic variants have been identified in an affected family member, molecular genetic testing for carrier testing of at-risk relatives and prenatal testing for pregnancies at increased risk are possible. Prenatal diagnosis by assay of plasmalogen biosynthesis is possible for pregnancies at 25% risk for RCDP1.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="rcdp.Diagnosis">
        <title>Diagnosis</title>
        <sec id="rcdp.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p><bold>Classic rhizomelic chondrodysplasia punctata type 1 (RCDP1)</bold> is recognized <bold>in the neonatal period</bold> by the presence of:</p>
          <list list-type="bullet">
            <list-item>
              <p>Cataracts</p>
            </list-item>
            <list-item>
              <p>Skeletal features. Classic findings include the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Rhizomelia (proximal shortening of the long bones)</p>
                </list-item>
                <list-item>
                  <p>Chondrodysplasia punctata (CDP): punctate calcifications observed in radiographs in the epiphyseal cartilage at the knee, hip, elbow, and shoulder that can be more extensive, involving the hyoid bone, larynx, costochondral junctions, and vertebrae. Metaphyseal abnormalities may be present.</p>
                </list-item>
                <list-item>
                  <p>Radiolucent coronal clefts of the vertebral bodies on lateral spine radiographs that represent unossified cartilage</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Classic RCDP1</bold> is recognized <bold>in childhood</bold> by the presence of:</p>
          <list list-type="bullet">
            <list-item>
              <p>Congenital cataracts</p>
            </list-item>
            <list-item>
              <p>Severe intellectual disability</p>
            </list-item>
            <list-item>
              <p>Profound growth retardation</p>
            </list-item>
            <list-item>
              <p>Resolution of the punctate calcifications leaving abnormal epiphyses and flared and irregular metaphyses after age one to three years</p>
            </list-item>
            <list-item>
              <p>Possible calcification of the intervertebral discs</p>
            </list-item>
          </list>
          <p><bold>Milder RCDP1 phenotype</bold> is recognized by:</p>
          <list list-type="bullet">
            <list-item>
              <p>Congenital cataracts</p>
            </list-item>
            <list-item>
              <p>Chondrodysplasia (manifesting as mild epiphyseal changes)</p>
            </list-item>
            <list-item>
              <p>Variable rhizomelia</p>
            </list-item>
            <list-item>
              <p>Milder intellectual disability and growth deficiency</p>
            </list-item>
          </list>
        </sec>
        <sec id="rcdp.Testing">
          <title>Testing</title>
          <p><bold>Biochemical tests.</bold> Three biochemical tests of peroxisome function are routinely used to confirm the diagnosis of RCDP1:</p>
          <list list-type="bullet">
            <list-item>
              <p>Red blood cell concentration of plasmalogens (<xref ref-type="table" rid="rcdp.T.values_for_red_blood_cell_plasmal">Table 1</xref>)</p>
            </list-item>
            <list-item>
              <p>Plasma concentration of phytanic acid (<xref ref-type="table" rid="rcdp.T.plasma_concentration_of_phytanic">Table 2</xref>)</p>
            </list-item>
            <list-item>
              <p>Plasma concentration of very long chain fatty acids (VLCFA)</p>
            </list-item>
          </list>
          <p>The finding of a deficiency of plasmalogens in red blood cells, increased plasma concentration of phytanic acid, and normal plasma concentration of very long chain fatty acids has consistently predicted the <italic toggle="yes">PEX7</italic> receptor defect in RCDP1.</p>
          <p>These assays are extremely specialized and are reliably performed in a limited number of laboratories worldwide.</p>
          <table-wrap id="rcdp.T.values_for_red_blood_cell_plasmal" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Values for Red Blood Cell Plasmalogens (Dimethylacetals) in RCDP1</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1" valign="middle" colspan="3" align="left" scope="colgroup" rowspan="1">C16 Saturated Dimethylacetals (DMA) to C16 Saturated Fatty Acid</th>
                </tr>
                <tr>
                  <th headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1" id="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"/>
                  <th headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1" id="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mean</th>
                  <th headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1" id="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Range</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1 hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Normal</bold>
                  </td>
                  <td headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1 hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">0.077&#x000b1;0.009</td>
                  <td headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1 hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">0.051-0.090</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1 hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Abnormal (RCDP1)</bold>
                  </td>
                  <td headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1 hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_1_1 hd_h_rcdp.T.values_for_red_blood_cell_plasmal_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">0.001-0.025&#x000a0;<sup>1</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Values are expressed as a ratio of C16 or C18 dimethylacetyls to fatty acid molecules.</p>
              </fn>
              <fn id="rcdp.TF.1.1">
                <label>1. </label>
                <p>Values are for the classic RCDP1 phenotype; individuals with a mild RCDP1 phenotype may fall outside this range.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <table-wrap id="rcdp.T.plasma_concentration_of_phytanic" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Plasma Concentration of Phytanic Acid in RCDP1</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"/>
                  <th id="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mean</th>
                  <th id="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Range</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Normal</bold>
                  </td>
                  <td headers="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.80 &#x000b5;g/mL &#x000b1; 0.40</td>
                  <td headers="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">0-2.5 &#x000b5;g/mL&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Abnormal (RCDP1)</bold>
                  </td>
                  <td headers="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_rcdp.T.plasma_concentration_of_phytanic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02264;300 &#x000b5;g/mL</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="rcdp.TF.2.1">
                <label>1. </label>
                <p>Plasma concentration of phytanic acid varies with dietary intake of animal fat. It can be normal in infants with RCDP1 because breast milk is low in phytanic acid and most formulas use vegetable fat.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>
            <bold>Assays in cultured skin fibroblasts</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Defective plasmalogen biosynthesis, defective phytanic acid (PA) oxidation, and normal VLCFA oxidation are confirmed in cultured fibroblasts.</p>
            </list-item>
            <list-item>
              <p>The absence of processed thiolase is determined in some laboratories.</p>
            </list-item>
            <list-item>
              <p>The fibroblast assays allow more complete characterization of peroxisomal functions and are critical in establishing the diagnosis in individuals with milder forms of RCDP1, whose plasmalogen levels may not be markedly abnormal.</p>
            </list-item>
          </list>
          <sec id="rcdp.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">PEX7</italic>, which encodes the receptor for a subset of peroxisomal matrix enzymes, is the only gene in which pathogenic variants are known to cause RCDP1.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="rcdp.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
              <label>Table 3. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Rhizomelic Chondrodysplasia Punctata Type 1</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_2">Test Method</th>
                    <th id="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_3">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Variant Detection Frequency&#x000a0;<sup>3</sup></th>
                  </tr>
                  <tr>
                    <th headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_4" id="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">2 variants</th>
                    <th headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_4" id="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">1 variant</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">PEX7</italic>
                    </td>
                    <td headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_4 hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">94%&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_4 hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">6%&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Leu292Ter</xref>, <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Gly217Arg</xref>, <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Ala218Val</xref>&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_1_4 hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_2_1 hd_h_rcdp.T.summary_of_molecular_genetic_test_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">51%-68% of pathogenic alleles</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="rcdp.TF.3.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="rcdp" object-id="rcdp.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="rcdp.TF.3.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="rcdp.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="rcdp.TF.3.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="rcdp.TF.3.4">
                  <label>4. </label>
                  <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="rcdp.TF.3.5">
                  <label>5. </label>
                  <p>Some laboratories may offer sequence analysis of select exons; exons tested may vary by laboratory.</p>
                </fn>
                <fn id="rcdp.TF.3.4_1">
                  <label>4. </label>
                  <p>Sequence analysis of <italic toggle="yes">PEX7</italic> coding and flanking intronic regions in 133 individuals with RCDP1 from the United States and the Netherlands identified 97% of pathogenic alleles [<xref ref-type="bibr" rid="rcdp.REF.braverman.2002.284">Braverman et al 2002</xref>, <xref ref-type="bibr" rid="rcdp.REF.motley.2002.612">Motley et al 2002</xref>]. Note: In all individuals with biochemically confirmed RCDP1, at least one pathogenic <italic toggle="yes">PEX7</italic> allele was identified.</p>
                </fn>
                <fn id="rcdp.TF.3.5_1">
                  <label>5. </label>
                  <p>Targeted analysis for pathogenic variants refers to testing for specific common variant(s). Variants detected may differ among laboratories.</p>
                </fn>
                <fn id="rcdp.TF.3.6">
                  <label>6. </label>
                  <p><xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Leu292Ter</xref> was the most common, accounting for 51% of alleles; <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">c.903+1G&#x0003e;C</xref>, <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Gly217Arg</xref>, and <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Ala218Val</xref> together account for 17% of alleles.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="rcdp.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>When the diagnosis of RCDP is considered, blood should be sent first for measurement of red blood cell plasmalogen, plasma phytanic acid, and plasma very long chain fatty acid concentrations.</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>When abnormalities are identified (see 1), the diagnosis is confirmed by enzymatic assays in cultured fibroblasts.</p>
            </list-item>
            <list-item>
              <label>3</label>
              <p>Molecular genetic testing is used to identify the two pathogenic variants in the proband, establish genotype-phenotype correlations, and enable prenatal diagnosis and carrier testing of at-risk relatives.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family. Prenatal diagnosis by biochemical testing is also possible; however, ideally the biochemical defects in cultured fibroblasts from an affected family member should be confirmed first.</p>
        </sec>
      </sec>
      <sec id="rcdp.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="rcdp.Clinical_Description">
          <title>Clinical Description</title>
          <sec id="rcdp.Classic_RCDP1">
            <title>Classic RCDP1</title>
            <p>The characteristic clinical features observed in RCDP1 are skeletal abnormalities, cataracts, growth retardation, and intellectual disability. The majority of children do not survive beyond the first decade of life and a proportion die in the neonatal period. In a review of 69 children with RCDP diagnosed by the Peroxisomal Diseases Laboratory at the Kennedy Krieger Institute, 60% of children survived the first year and 39% the second; a few survived beyond age ten years. In a review of 35 affected children older than age one month, <xref ref-type="bibr" rid="rcdp.REF.white.2003.332">White et al [2003]</xref> reported 90% survival at age one year, 50% survival to age six years, and approximately 20% survival at age 12 years. Most deaths were secondary to respiratory complications. Clinical experience suggests that neonatal deaths have been associated with congenital heart disease or pulmonary hypoplasia [<xref ref-type="bibr" rid="rcdp.REF.oswald.2011.3160">Oswald et al 2011</xref>].</p>
            <p><bold>Skeletal findings.</bold> Infants with RCDP1 have bilateral shortening of the humerus and to a lesser degree the femur. They typically have contractures and stiff, painful joints, causing irritability in infancy. Cartilaginous structures of the face are affected, resulting in frontal bossing and a short, concave nasal ridge.</p>
            <p><bold>Cataracts.</bold> Bilateral cortical cataracts develop in virtually all affected individuals. They are usually present at birth or appear in the first few months of life and are progressive.</p>
            <p><bold>Growth retardation.</bold> Whereas birth weight, length, and head circumference are often at the lower range of normal, postnatal growth deficiency is profound.</p>
            <p><bold>Intellectual disability.</bold> Developmental quotients are below 30. Early developmental skills such as smiling and recognizing voices are achieved by most children with RCDP, but at delayed ages. Skills usually achieved in normal children beyond age six months are never seen [<xref ref-type="bibr" rid="rcdp.REF.white.2003.332">White et al 2003</xref>].</p>
            <p>The majority of children develop seizures.</p>
            <p>Routine brain imaging is normal or has shown cerebral and cerebellar atrophy with enlargement of the ventricles and CSF spaces [<xref ref-type="bibr" rid="rcdp.REF.powers.1999.129">Powers et al 1999</xref>]. MR imaging and MR spectroscopy have shown delayed myelinization, signal abnormalities in supratentorial white matter, decreased choline-to-creatine ratios, and increased levels of mobile lipids, thought to reflect the deficiency of plasmalogens, which are substantial components of myelin [<xref ref-type="bibr" rid="rcdp.REF.alkan.2003.77">Alkan et al 2003</xref>, <xref ref-type="bibr" rid="rcdp.REF.bamsmengerink.2006.798">Bams-Mengerink et al 2006</xref>].</p>
            <p><bold>Other.</bold> Most children with RCDP1 have recurrent respiratory tract infections caused by neurologic compromise, aspiration, immobility, and a small chest with restricted expansion.</p>
            <p>Radiologic and MRI evidence of multilevel cervical stenosis with or without compression of the spinal cord has been observed. Spinal cord compression may complicate the neurologic picture, which often includes spastic quadriplegia [<xref ref-type="bibr" rid="rcdp.REF.khanna.2001.63">Khanna et al 2001</xref>].</p>
            <p>Ichthyotic skin changes are noted in fewer than one third of individuals.</p>
            <p>Approximately 5%-10% of individuals have a cleft of the soft palate.</p>
            <p>Other malformations observed in individuals with RCDP1 include congenital heart disease and ureteropelvic junction (UPJ) obstruction.</p>
          </sec>
          <sec id="rcdp.Mild_RCDP1">
            <title>Mild RCDP1</title>
            <p>Only a few individuals with milder forms of RCDP1 have been described. All have had chondrodysplasia and cataracts but variable expression of punctate calcifications, rhizomelia, growth retardation, and intellectual disability [<xref ref-type="bibr" rid="rcdp.REF.braverman.2002.284">Braverman et al 2002</xref>, <xref ref-type="bibr" rid="rcdp.REF.bamsmengerink.2006.798">Bams-Mengerink et al 2006</xref>]. One child, presenting with developmental delay and poor growth, subsequently developed <related-object link-type="booklink" source-id="gene" document-id="rp-overview" document-type="chapter">retinitis pigmentosa</related-object> and peripheral neuropathy, features overlapping those of adult <related-object link-type="booklink" source-id="gene" document-id="refsum" document-type="chapter">Refsum disease</related-object> [<xref ref-type="bibr" rid="rcdp.REF.braverman.2002.284">Braverman et al 2002</xref>]. Thus, it is likely that a continuum of phenotypes will emerge within the RCDP group. Molecular analysis of <italic toggle="yes">PEX7</italic> may identify individuals with unusual phenotypes.</p>
          </sec>
        </sec>
        <sec id="rcdp.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The degree of plasmalogen deficiency correlates directly with phenotypic severity:</p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals in the milder RCDP group exhibit intermediate defects in fibroblast plasmalogen synthesis and RBC plasmalogen concentrations that are approximately 30% of the mean in controls and more than two standard deviations above the mean in children with classic RCDP.</p>
            </list-item>
            <list-item>
              <p>Individuals with more variant phenotypes have near-normal plasmalogen biochemistry.</p>
            </list-item>
            <list-item>
              <p>Defects in phytanic acid oxidation in fibroblast assays are severe in all <italic toggle="yes">PEX7</italic> defects.</p>
            </list-item>
          </list>
          <p>Some correlations between the predicted severity of <italic toggle="yes">PEX7</italic> pathogenic variants and phenotype have emerged:</p>
          <list list-type="bullet">
            <list-item>
              <p>All individuals homozygous for the <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Leu292Ter</xref> pathogenic variant studied thus far have had classic RCDP1.</p>
            </list-item>
            <list-item>
              <p>In individuals who are compound heterozygotes for <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Leu292Ter</xref> and another pathogenic variant, the effect of the other allele is important in determining the phenotype. Several <italic toggle="yes">PEX7</italic> alleles that are associated with a milder RCDP phenotype, adult Refsum disease, or isolated congenital cataracts have been identified. It is predicted that these encode either residual amounts of a normal Pex7 protein or a defective protein with residual function [<xref ref-type="bibr" rid="rcdp.REF.braverman.2002.284">Braverman et al 2002</xref>, <xref ref-type="bibr" rid="rcdp.REF.motley.2002.612">Motley et al 2002</xref>, <xref ref-type="bibr" rid="rcdp.REF.van_den_brink.2003.471">van den Brink et al 2003</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="rcdp.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance is complete and the same for either sex.</p>
        </sec>
        <sec id="rcdp.Nomenclature">
          <title>Nomenclature</title>
          <p>RCDP1 is one of two groups of peroxisome biogenesis disorders (PBD). The other PBD group is the <related-object link-type="booklink" source-id="gene" document-id="pbd" document-type="chapter">Zellweger syndrome spectrum</related-object>.</p>
          <p>Although individuals with RCDP1 have a perturbation in matrix protein import consistent with a peroxisomal assembly defect, they have a biochemical, cellular, and clinical phenotype distinct from PBD of the Zellweger syndrome spectrum.</p>
        </sec>
        <sec id="rcdp.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of RCDP1 is estimated to be lower than 1:100,000. The disorder is pan ethnic. The high frequency of the <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Leu292Ter</xref> allele is secondary to a founder effect in individuals of Northern European descent [<xref ref-type="bibr" rid="rcdp.REF.braverman.2000.181">Braverman et al 2000</xref>].</p>
        </sec>
      </sec>
      <sec id="rcdp.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Defects in <italic toggle="yes">PEX7</italic> can result in at least two phenotypes distinct from RCDP1:</p>
        <list list-type="bullet">
          <list-item>
            <p>Isolated congenital cataracts</p>
          </list-item>
          <list-item>
            <p>A disorder similar to adult <related-object link-type="booklink" source-id="gene" document-id="refsum" document-type="chapter">Refsum disease</related-object></p>
          </list-item>
        </list>
        <p>In both disorders, plasmalogen biosynthesis is nearly normal, although phytanic acid oxidation in skin fibroblast assays is severely reduced [<xref ref-type="bibr" rid="rcdp.REF.braverman.2002.284">Braverman et al 2002</xref>, <xref ref-type="bibr" rid="rcdp.REF.van_den_brink.2003.471">van den Brink et al 2003</xref>].</p>
      </sec>
      <sec id="rcdp.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The classic RCDP1 phenotype can be mimicked by isolated deficiencies of either of two peroxisomal enzymes involved in plasmalogen biosynthesis, as well as by severe Conradi-H&#x000fc;nermann syndrome. In addition, several different disorders, described below, have similar punctate cartilaginous changes and various combinations of limb asymmetry, short stature, intellectual disability, cataracts, and skin changes. The radiologic finding of chondrodysplasia punctata (CDP) has been observed in various metabolic disorders, skeletal dysplasias, chromosome abnormalities, and teratogen exposures. Exhaustive classifications of CDP have been published [<xref ref-type="bibr" rid="rcdp.REF.irving.2008.229">Irving et al 2008</xref>].</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Rhizomelic chondrodysplasia punctata, type 2 (RCDP2) and type 3 (RCDP3).</bold> RCDP2 is caused by deficiency of the peroxisomal enzyme dihydroxyacetone phosphate acyltransferase, encoded by <italic toggle="yes">GNPAT</italic> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/602744">602744</ext-link>). RCDP3 is caused by deficiency of the peroxisomal enzyme alkyl-dihydroxyacetone phosphate synthase, encoded by <italic toggle="yes">AGPS</italic> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/600121">600121</ext-link>). The clinical phenotypes resemble that seen in RCDP1, emphasizing the role of plasmalogen deficiency in determining the RCDP phenotype. RCDP2 and RCDP3 are inherited in an autosomal recessive manner and are rarer than RCDP1. The specific enzyme defect is confirmed by measurement of the enzyme activity in cultured skin fibroblasts and/or identification of two pathogenic variants by sequence analysis of <italic toggle="yes">AGPS</italic> or <italic toggle="yes">GNPAT</italic>.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="cdp1-xlr" document-type="chapter"><bold>X-linked recessive chondrodysplasia punctata</bold></related-object><bold>, or brachytelephalangic type (CDPX1)</bold> is caused by defects in arylsulfatase E (<italic toggle="yes">ARSE</italic>), a vitamin K-dependent enzyme. Affected males have hypoplasia of the distal phalanges without limb shortening or cataracts. The diagnosis is confirmed by molecular genetic testing. Contiguous gene deletions involving <italic toggle="yes">ARSE</italic> result in more complex phenotypes, including ichthyosis and corneal opacities resulting from steroid sulfatase deficiency.</p>
          </list-item>
          <list-item>
            <p><bold>Warfarin embryopathy and other fetal vitamin K deficiencies</bold> (including vitamin K epoxide reductase deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/277450">277450</ext-link>]) are phenotypically similar to CDPX1.</p>
          </list-item>
          <list-item>
            <p><bold>Maternal systemic lupus erythematosis (SLE)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/152700">152700</ext-link>) and other maternal autoimmune diseases can cause CDP in the offspring that is phenotypically similar to CDPX1.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="x-dcdp" document-type="chapter"><bold>X-linked dominant chondrodysplasia punctata</bold></related-object><bold>, or Conradi-H&#x000fc;nermann syndrome (CDPX2)</bold> is usually lethal in males. It is caused by defects in sterol- &#x00394;8-isomerase which catalyzes an intermediate step in the conversion of lanosterol to cholesterol. X-chromosome inactivation in females results in phenotypic variability and asymmetric findings. Cataracts are sectorial and limb shortening is rhizomesomelic and usually asymmetric. Severely affected infants have bilateral findings resembling those of RCDP1. The diagnosis is confirmed by measuring the plasma concentration of sterols, which show accumulation of the precursors 8(9)-cholestenol and 8-dehydrocholesterol and/or identification of two pathogenic variants by molecular genetic testing of <italic toggle="yes">EBP</italic>.</p>
          </list-item>
          <list-item>
            <p><bold>Chondrodysplasia punctata, tibia-metacarpal type</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/118651">118651</ext-link>) and <bold>humero-metacarpal type</bold> [<xref ref-type="bibr" rid="rcdp.REF.fryburg.1996.493">Fryburg &#x00026; Kelly 1996</xref>] are inherited in an autosomal dominant manner. The gene(s) in which mutation is causative are unknown. Affected individuals have short metacarpals with shortening of various long bones. No cataracts or skin changes are present.</p>
          </list-item>
        </list>
      </sec>
      <sec id="rcdp.Management">
        <title>Management</title>
        <sec id="rcdp.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with rhizomelic chondrodysplasia punctata type I (RCDP1), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Full skeletal survey (with flexion and extension views of the neck)</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic examination</p>
            </list-item>
            <list-item>
              <p>Growth parameters</p>
            </list-item>
            <list-item>
              <p>Developmental assessment</p>
            </list-item>
            <list-item>
              <p>MR imaging of brain (with MR spectroscopy)</p>
            </list-item>
            <list-item>
              <p>Cardiac ultrasound examination</p>
            </list-item>
            <list-item>
              <p>Renal ultrasound examination</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="rcdp.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Management is supportive and limited because of the multiple handicaps present at birth and the poor outcome.</p>
          <p>Cataract extraction may preserve some vision.</p>
          <p>Physical therapy is recommended to assist in the improvement of contractures; orthopedic procedures have improved function in some individuals.</p>
        </sec>
        <sec id="rcdp.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Dietary restriction of phytanic acid to avoid the consequences of phytanic acid accumulation over time may benefit individuals with milder forms of RCDP.</p>
        </sec>
        <sec id="rcdp.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Poor feeding and recurrent aspiration necessitate the placement of a gastrostomy tube. Note: Improved nutrition does not enhance linear growth.</p>
          <p>Individuals with RCDP1 require good pulmonary toilet and careful attention to respiratory function. Influenza vaccine and RSV monoclonal antibody should be provided.</p>
          <p>Low plasmalogen levels can be associated with low levels of docosohexanoic acid (DHA). DHA can be measured in plasma; oral supplementation should be provided if levels are low.</p>
        </sec>
        <sec id="rcdp.Surveillance">
          <title>Surveillance</title>
          <p>Based on a retrospective review of the natural history of 35 individuals with RCDP, <xref ref-type="bibr" rid="rcdp.REF.white.2003.332">White et al [2003]</xref> provide health supervision guidelines for primary caretakers of children with RCDP, including the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Growth curves that allow weight comparisons to help determine the need for gastrostomy</p>
            </list-item>
            <list-item>
              <p>The ages at which developmental milestones are achieved to provide realistic expectations</p>
            </list-item>
            <list-item>
              <p>Recommendations for medical assessments including seizure control, vision, hearing, orthopedic care, and prevention of respiratory infections and contractures</p>
            </list-item>
          </list>
        </sec>
        <sec id="rcdp.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="rcdp.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="rcdp.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="rcdp.Other">
          <title>Other</title>
          <p>Data suggest that oral plasmalogen supplementation using alkylglycerol sources can increase tissue plasmalogen concentrations in rodents and red blood cell (RBC) plasmalogen concentrations in individuals with <related-object link-type="booklink" source-id="gene" document-id="pbd" document-type="chapter">Zellweger syndrome spectrum disorders</related-object>. Anecdotal reports of alkylglycerol supplementation in a few individuals with classic RCDP1 have not indicated dramatic clinical benefit; however, alkylglycerol supplementation has not yet been studied in a systematic fashion. Studies in <italic toggle="yes">Pex7</italic>-deficient mouse models have shown that plasmalogen precursors can partially recover plasmalogen levels in body tissues, but not in brain [<xref ref-type="bibr" rid="rcdp.REF.brites.2004.219">Brites et al 2004</xref>, <xref ref-type="bibr" rid="rcdp.REF.wood.2011.182">Wood et al 2011</xref>]</p>
          <p>Nonsense suppressor drugs were unable to recover protein production in individuals with the common <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Leu292Ter</xref> allele [<xref ref-type="bibr" rid="rcdp.REF.dranchak.2011.1250">Dranchak et al 2011</xref>].</p>
        </sec>
      </sec>
      <sec id="rcdp.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="rcdp.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>RCDP1 is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="rcdp.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of a proband are obligate heterozygotes (carriers) and therefore carry one pathogenic allele.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of a proband has a 25% chance of inheriting both pathogenic alleles and being affected, a 50% chance of inheriting one pathogenic allele and being an unaffected carrier, and a 25% chance of inheriting both normal alleles.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Affected individuals do not reproduce.</p>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="rcdp.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carriers cannot be identified by biochemical methods.</p>
          <p>Carrier testing of at-risk relatives using molecular genetic techniques is possible if the pathogenic variants have been identified in an affected family member.</p>
        </sec>
        <sec id="rcdp.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="rcdp.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p><bold>Molecular genetic testing.</bold> If the <italic toggle="yes">PEX7</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing for this disease/gene or custom prenatal testing.</p>
          <p><bold>Biochemical testing.</bold> Prenatal diagnosis for pregnancies at 25% risk for RCDP1 is also possible by assay of plasmalogen biosynthesis in cultured chorionic villi obtained by CVS (usually performed at ~10-12 weeks' gestation) or in cultured amniocytes obtained by amniocentesis (usually performed at ~15-18 weeks' gestation).</p>
          <p>The determination of enzyme activity of alkyl-dihydroxyacetone phosphate synthase (AGPS) and the subcellular localization of peroxisomal thiolase have also been performed successfully on uncultured chorionic villi.</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p><bold>Ultrasound examination.</bold> Rhizomelia and punctate calcifications have been noted on ultrasound examination as early as 18 to 19 weeks [<xref ref-type="bibr" rid="rcdp.REF.krakow.2003.467">Krakow et al 2003</xref>, <xref ref-type="bibr" rid="rcdp.REF.zwijnenburg.2010.162">Zwijnenburg et al 2010</xref>]. Others have reported these findings along with bilateral cataracts at 32 weeks, and epiphyseal stippling shown four weeks later [<xref ref-type="bibr" rid="rcdp.REF.basbug.2005.171">Basbug et al 2005</xref>]. Homozygosity of the <xref ref-type="table" rid="rcdp.T.selected_pex7_pathogenic_variants">p.Leu292Ter</xref> variant in <italic toggle="yes">PEX7</italic> was verified in the case reported by <xref ref-type="bibr" rid="rcdp.REF.zwijnenburg.2010.162">Zwijnenburg et al [2010]</xref>.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variants have been identified in an affected family member.</p>
        </sec>
      </sec>
      <sec id="rcdp.Resources">
        <title>Resources</title>
      </sec>
      <sec id="rcdp.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="rcdp.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><bold>Role of the peroxisome targeting signal 2 receptor, PEX7, in peroxisome assembly.</bold> Peroxisomal matrix enzymes are synthesized on free polyribosomes and directed to the peroxisome by cytosolic receptors. The peroxisome targeting signal 1 receptor (encoded by <italic toggle="yes">PEX5</italic>) binds a C-terminal peroxisome targeting signal, PTS1, present on most matrix proteins. PEX7 binds an N-terminal PTS2, present on three. The two receptors themselves interact and carry their protein cargo to the peroxisome membrane; the matrix proteins are then translocated inside, the import complex is disassembled, and the receptors are recycled for another round of import. This import process, along with the formation of new peroxisomes and division of existing ones, is termed peroxisome biogenesis. Fourteen human proteins are required for peroxisome biogenesis; collectively they are called peroxins and they are encoded by <italic toggle="yes">PEX</italic> genes.</p>
          <p><bold>Metabolic pathways dependent on PEX7.</bold> The three PTS2 proteins transported to the peroxisome by PEX7 are alkyl-dihydroxyacetone phosphate synthase (AGPS), phytanoyl-CoA hydroxylase (PhyH), and peroxisomal 3-ketoacyl-CoA thiolase (ACAA1).</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>AGPS</bold> catalyzes the initial steps of plasmalogen biosynthesis in a complex with the PTS1 protein, dihydroxyacetone phosphate acyltransferase (GNPAT). Plasmalogens are a class of membrane phospholipids, in which the fatty acid at the C1 position of the glycerophospholipid is replaced by a fatty alcohol. Plasmalogens are present in significant proportions in plasma membranes and myelin, and their specific functions are now being investigated [<xref ref-type="bibr" rid="rcdp.REF.braverman.2012.1442">Braverman &#x00026; Moser 2012</xref>]. These compounds may protect against oxidative damage, be required for membrane fusion and fission processes, and function as lipid messengers. Since isolated defects in GNPAT or AGPS also result in RCDP (RCDP types 2 and 3), plasmalogen deficiency must play a major role in the pathogenesis of this disorder.</p>
            </list-item>
            <list-item>
              <p><bold>PhYH</bold> catalyzes the initial step in the catabolism of phytanic acid, a 16-carbon methyl-branched fatty acid of dietary origin. Isolated defects in PhYH cause adult <related-object link-type="booklink" source-id="gene" document-id="refsum" document-type="chapter">Refsum disease</related-object>.</p>
            </list-item>
            <list-item>
              <p><bold>Peroxisomal thiolase (ACAA1)</bold> catalyzes the last step in beta oxidation of very long straight-chain fatty acids. Beta oxidation is normal in RCDP1, presumably because the thiolase activity of sterol carrier protein-X, a PTS1 protein, compensates for this deficiency.</p>
            </list-item>
            <list-item>
              <p>Other proteins with PTS2 targeting signals have been recently identified by bioinformatics and proteomics experiments [<xref ref-type="bibr" rid="rcdp.REF.wiese.2007.2045">Wiese et al 2007</xref>, <xref ref-type="bibr" rid="rcdp.REF.kunze.2011.45048">Kunze et al 2011</xref>]. Their role in human disease caused by mutation of <italic toggle="yes">PEX7</italic> is not known.</p>
            </list-item>
          </list>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">PEX7</italic> contains ten exons that span 91 kb of genomic DNA. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="rcdp" object-id="rcdp.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign allelic variants.</bold> No benign variants have been identified yet in the coding sequence.</p>
          <p><bold>Pathogenic allelic variants.</bold> Approximately 39 unique <italic toggle="yes">PEX7</italic> pathogenic variants have been identified thus far (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.dbpex.org">www.dbpex.org</ext-link>). The majority are nonsense, missense, or splice site variants, small insertions, or deletions. The pathogenic allele p.Leu292Ter accounts for 51% of alleles; less common alleles are c.903+1G&#x0003e;C, p.Gly217Arg, p.Ala218Val, and p.Tyr40Ter.</p>
          <p>Alleles associated with milder RCDP phenotypes, variant phenotypes, or adult Refsum disease are either missense alleles located on the surfaces of the PEX7 protein and thus unlikely to disrupt its structural integrity (p.Ser25Phe, p.His285Arg, p.Thr14Pro), or 'leaky' alleles, potentially able to generate residual amounts of normal PEX7 protein (c.-45C&#x0003e;T,c.442-10A&#x0003e;G) and re-initiate translation in-frame (p.His18ArgfsTer35) or at a downstream methionine residue (p.Gly7ValfsTer51) [<xref ref-type="bibr" rid="rcdp.REF.braverman.2002.284">Braverman et al 2002</xref>, <xref ref-type="bibr" rid="rcdp.REF.motley.2002.612">Motley et al 2002</xref>, <xref ref-type="bibr" rid="rcdp.REF.van_den_brink.2003.471">van den Brink et al 2003</xref>].</p>
          <table-wrap id="rcdp.T.selected_pex7_pathogenic_variants" position="anchor" orientation="portrait">
            <label>Table 4. </label>
            <caption>
              <p>Selected <italic toggle="yes">PEX7</italic> Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change <break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                  <th id="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.-45C&#x0003e;T</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_3" rowspan="11" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/197927204">NM_000288.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/4505731">NP_000279.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.340-10A&#x0003e;G<break/>(IVS3-10A&#x0003e;G)</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.45_52dupGGGACGCC<break/>(52insGGGACGCC)</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His18ArgfsTer35</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.12_18dupGTGCGGT</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly7ValfsTer51</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.74C&#x0003e;T</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser25Phe</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.854A&#x0003e;G</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His285Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.40A&#x0003e;C</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr14Pro</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.903+1G&#x0003e;C<break/>(IVS9+1G&#x0003e;C)</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.649G&#x0003e;A</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly217Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.653C&#x0003e;T</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala218Val</td>
                </tr>
                <tr>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.875T&#x0003e;A</td>
                  <td headers="hd_h_rcdp.T.selected_pex7_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu292Ter</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="rcdp.TF.4.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> PEX7, the peroxisome-targeting signal 2 receptor, is a 323-amino acid protein with serial WD40 repeats (short structural motif of approximately 40 amino acids, often terminating in a tryptophan-aspartic acid (W-D) dipeptide). These repeat domains fold into blades of a propeller-like structure, which resembles a torus on its side and provides several surfaces for protein interactions [<xref ref-type="bibr" rid="rcdp.REF.braverman.2002.284">Braverman et al 2002</xref>]. PEX7 is a receptor for a subclass of peroxisomal matrix enzymes and binds the PTS2 signal at the N-terminus of these proteins. PEX7 carries its cargo to the peroxisome membrane by virtue of its interaction with PEX5.</p>
          <p><bold>Abnormal gene product.</bold> Defects in <italic toggle="yes">PEX7</italic> result in deficient activity of PTS2 enzymes, but other peroxisomal functions remain intact. Fibroblast assays show that PTS2 proteins remain cytosolic in individuals with RCDP1 and are degraded, but PTS1 proteins are imported into peroxisomes normally. Peroxisome morphology is normal in fibroblasts but abnormal in liver, according to several case reports.</p>
        </sec>
      </sec>
      <sec id="rcdp.References">
        <title>References</title>
        <sec id="rcdp.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="rcdp.Literature_Cited.reflist0">
            <ref id="rcdp.REF.alkan.2003.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alkan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutlu</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yakinci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sigirci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aslan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarac</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Delayed myelination in a rhizomelic chondrodysplasia punctata case: MR spectroscopy findings.</article-title>
                <source>Magn Reson Imaging</source>
                <volume>21</volume>
                <fpage>77</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">12620550</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.bamsmengerink.2006.798">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bams-Mengerink</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majoie</surname>
                    <given-names>CBLM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheurer</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll-The</surname>
                    <given-names>BT</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>MRI of the brain and certical spinal cord in rhizomelic chondrodysplasia punctata.</article-title>
                <source>Neurology</source>
                <volume>66</volume>
                <fpage>798</fpage>
                <lpage>803</lpage>
                <pub-id pub-id-type="pmid">16567694</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.basbug.2005.171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Basbug</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serin</surname>
                    <given-names>IS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozcelik</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gunes</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akcakus</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayyar</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Prenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata by detection of rhizomelic shortening and bilateral cataracts.</article-title>
                <source>Fetal Diagn Ther</source>
                <volume>20</volume>
                <fpage>171</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15824492</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.braverman.2002.284">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obie</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Douglas</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakraborty</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boneh</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype.</article-title>
                <source>Hum Mutat</source>
                <volume>20</volume>
                <fpage>284</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">12325024</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.braverman.2000.181">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>PEX7 gene structure, alternative transcripts, and evidence for a founder haplotype for the frequent RCDP allele, L292ter.</article-title>
                <source>Genomics</source>
                <volume>63</volume>
                <fpage>181</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">10673331</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.braverman.2012.1442">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Functions of plasmalogen lipids in health and disease.</article-title>
                <source>Biochim Biophys Acta.</source>
                <volume>1822</volume>
                <fpage>1442</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">22627108</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.brites.2004.219">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brites</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Functions and biosynthesis of plasmalogens in health and disease.</article-title>
                <source>Biochim Biophys Acta</source>
                <volume>1636</volume>
                <fpage>219</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">15164770</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.dranchak.2011.1250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dranchak</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Pietro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snowden</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oesch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hacia</surname>
                    <given-names>JG</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations.</article-title>
                <source>J Cell Biochem.</source>
                <volume>112</volume>
                <fpage>1250</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21465523</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.fryburg.1996.493">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fryburg</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>TE</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Chondrodysplasia punctata, humero-metacarpal type: a second case.</article-title>
                <source>Am J Med Genet.</source>
                <volume>64</volume>
                <fpage>493</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8862628</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.irving.2008.229">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Irving</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chitty</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Chondrodysplasia punctata: a clinical diagnostic and radiological review.</article-title>
                <source>Clin Dysmorphol</source>
                <volume>17</volume>
                <fpage>229</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">18978650</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.khanna.2001.63">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Khanna</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sponseller</surname>
                    <given-names>PD</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Cervical stenosis secondary to rhizomelic chondrodysplasia punctata.</article-title>
                <source>Am J Med Genet</source>
                <volume>99</volume>
                <fpage>63</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11170096</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.krakow.2003.467">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Krakow</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>J</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Poehl</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimoin</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platt</surname>
                    <given-names>LD</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Use of three-dimensional ultrasound imaging in the diagnosis of prenatal-onset skeletal dysplasias.</article-title>
                <source>Ultrasound Obstet Gynecol</source>
                <volume>21</volume>
                <fpage>467</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">12768559</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.kunze.2011.45048">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kunze</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuberger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maurer-Stroh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ma</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eck</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmid</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eisenhaber</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Structural requirements for interaction of peroxisomal targeting signal 2 and its receptor PEX7.</article-title>
                <source>J Biol Chem.</source>
                <volume>286</volume>
                <fpage>45048</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">22057399</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.motley.2002.612">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Motley</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brites</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogenhout</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haasjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benne</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabak</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1.</article-title>
                <source>Am J Hum Genet</source>
                <volume>70</volume>
                <fpage>612</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">11781871</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.oswald.2011.3160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oswald</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golden</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Rhizomelic chondrodysplasia punctata type 1 and fulminant neonatal respiratory failure, a case report and discussion of pathophysiology.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>155A</volume>
                <fpage>3160</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">22052861</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.powers.1999.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Powers</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kenjarski</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Cerebellar atrophy in chronic rhizomelic chondrodysplasia punctata: a potential role for phytanic acid and calcium in the death of its Purkinje cells.</article-title>
                <source>Acta Neuropathol (Berl)</source>
                <volume>98</volume>
                <fpage>129</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">10442551</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.van_den_brink.2003.471">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van den Brink</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brites</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haasjes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wierzbicki</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert-Hamill</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Belleroche</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Identification of PEX7 as the second gene involved in Refsum disease.</article-title>
                <source>Am J Hum Genet</source>
                <volume>72</volume>
                <fpage>471</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12522768</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.white.2003.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Modaff</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holland-Morris</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pauli</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Natural history of rhizomelic chondrodysplasia punctata.</article-title>
                <source>Am J Med Genet</source>
                <volume>118A</volume>
                <fpage>332</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">12687664</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.wiese.2007.2045">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wiese</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gronemeyer</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ofman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunze</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grou</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eisenacher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schollenberger</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korosec</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schliebs</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Just</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azevedo</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warscheid</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Proteomics characterization of mouse kidney peroxisomes by tandem mass spectrometry and protein correlation profiling.</article-title>
                <source>Mol Cell Proteomics.</source>
                <volume>6</volume>
                <fpage>2045</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">17768142</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.wood.2011.182">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khan</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehrmantraut</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cui</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodenowe</surname>
                    <given-names>DB</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor.</article-title>
                <source>Lipids Health Dis.</source>
                <volume>10</volume>
                <fpage>182</fpage>
                <pub-id pub-id-type="pmid">22008564</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.zwijnenburg.2010.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zwijnenburg</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deurloo</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meijers-Heijboer</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Vugt</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan-Sindhunata</surname>
                    <given-names>MB</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Second trimester prenatal diagnosis of rhizomelic chondrodysplasia punctata type 1 on ultrasound findings.</article-title>
                <source>Prenat Diagn.</source>
                <volume>30</volume>
                <fpage>162</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">20014169</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="rcdp.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="rcdp.Suggested_Reading.reflist0">
            <ref id="rcdp.REF.gould.2014">
              <mixed-citation publication-type="webpage">Gould SJ, Raymond GV, Valle D. The peroxisome biogenesis disorders. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> New York, NY: McGraw-Hill. Chap 129. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/content.aspx?sectionid=62640212&#x00026;bookid=971">online</ext-link>. 2014. Accessed 12-2-15.</mixed-citation>
            </ref>
            <ref id="rcdp.REF.steinberg.2006.1733">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steinberg</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dodt</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>GV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>HW</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Peroxisome biogenesis disorders.</article-title>
                <source>Biochim Biophys Acta.</source>
                <volume>1763</volume>
                <fpage>1733</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">17055079</pub-id>
              </element-citation>
            </ref>
            <ref id="rcdp.REF.wanders.2006.1707">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Peroxisomal disorders: the single peroxisomal enzyme deficiencies.</article-title>
                <source>Biochim Biophys Acta.</source>
                <volume>1763</volume>
                <fpage>1707</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">17055078</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="rcdp.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="rcdp.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>13 September 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>2 March 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>18 July 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>7 February 2005 (cd) Revision: test availability</p>
            </list-item>
            <list-item>
              <p>26 February 2004 (cd) Revision: test availability</p>
            </list-item>
            <list-item>
              <p>13 February 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>16 November 2001 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>10 June 2001 (nb) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
